Webinar Recording | Webinar Summary | Slides

Biosimilars continue to be a controversial subject long after Congress created a pathway for their approval. The Value & Innovation Forum prides itself on creating forums that present all sides of an issue as well as new and interesting angles beyond the hotly debated. This session provides an interesting discussion about the “rebate wall” controversy in biosimilars, a patient perspective, and where the FDA is headed next.
Speakers
John M. Clymer, Executive Director, National Forum for Heart Disease & Stroke Prevention
Nicole Braccio, PharmD, Policy Director, National Patient Advocate Foundation
Christine Simmon, JD, Senior Vice President, Policy & Strategic Alliances, Executive Director, Biosimilars Council, Association for Accessible Medicines
Sarah Yim, MD, Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation & Research, U.S. Food and Drug Administration
Chad Pettit, Executive Director, Global Value Access and Policy, Amgen
Madelaine Feldman, MD, Practicing Rheumatologist, Founding Member & Past President, Rheumatology Alliance of Louisiana
Agenda
WELCOME
John M. Clymer, Executive Director, National Forum for Heart Disease & Stroke Prevention
Bio
MODERATOR

Nicole Braccio, PharmD, Policy Director, National Patient Advocate Foundation
Bio
Panelists
Christine Simmon, Senior Vice President, Policy & Strategic Alliances, Executive Director, Biosimilars Council, Association for Accessible Medicines
Bio
Sarah Yim, MD, Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation & Research, U.S. Food and Drug Administration
Bio
Chad Pettit, Executive Director, Global Value Access and Policy, Amgen
Bio
Madelaine Feldman, MD, Practicing Rheumatologist, President, Coalition of State Rheumatology Organizations
Bio
Articles
Formulary Construction in America: ‘Perfectly Legal’ and ‘Perfectly Wrong
Op-Ed: Debate Over Pharmacy Benefit Managers a Matter of Price vs. Cost
Washington Must Change the System That Encourages High Drug Prices
White Paper
Lessons for the United States on Europe’s Biosimilar Experience
Websites
FDA Biosimilars for access to educational materials and information about biosimilar and interchangeable products.
Drugs@FDA for information on all FDA approved drug products, including labeling and review information.
FDA Advisory Committees for drug advisory committee meetings and materials related to biosimilars
FDA Purple Book a database of Licensed Biological Products for information on biological products, including if products are biosimilar to a reference product.
Amgen Biosimilars